Df-IA2BM-Zr-89 - ImaginAb

Drug Profile

Df-IA2BM-Zr-89 - ImaginAb

Alternative Names: [89Zr]Df-IAB2M; IAB2M; IAB2M PSMA minibody; IAB2M PSMA PET imaging agent

Latest Information Update: 16 Aug 2016

Price : $50

At a glance

  • Originator ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Glioma

Most Recent Events

  • 01 Jul 2016 ImaginAb completes a phase II trial for Prostate cancer (Diagnosis) in USA (NCT02349022)
  • 01 Jun 2016 ImaginAb completes a phase I/II trial in Prostate caner (Diagnosis, Metastatic disease) in USA (NCT01923727)
  • 06 Jan 2016 Updated efficacy data from a phase I/II trial in Prostate cancer (Diagnosis) released by ImaginAb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top